Embryonic Stem Cells used to Treat 35 Patients
We at StemCellPatents.com have been most fascinated by the first clinical report of using embryonic stem cell-derived products .
In response to our coverage of this event, the senior author of the paper, Dr. H.L. Trivedi has requested us to post the following:
" Thank you for your interest in our work. I would like to draw the attention of your readership that this patient will be finishing 1 year without any rejection/ teratoma. He is doing well. We have also implemented the same protocol in 35 more patients successfully. H.L. Trivedi "
We at StemCellPatents.com are very fascinated by this work. Regardless of ethical concerns some individuals may have about this work, these treated patients offer INCREDIBLE insight into the clinical future of embryonic stem cells. Accordingly we will seek to establish a dialogue with Dr. Trivedi...So please, in the comments section below, ask any questions that you feel need answering as to scientific/clinical matters
We will compile the questions and seek an interview with Dr. Trivedi as a follow up to his original communication with us.
By opening up such a dialogue, we feel that much progress can be made and duplication of efforts can be avoided.
Social & Bookmarking:
7 Comments | Add Comment
StemCellPatents.com said...
Dear Notch1,
We really appreciate your ongoing comments and contributions to this website. Your questions will definately be addressed in the interview.
Additionally, it is obvious that you are very active in this field and we would welcome any review or other type of paper you wish to submit to our journal.
Best regards,
StemCellPatents.com Team
SSlavin said...
You should ask Michael West (ACT) if he knows about this paper and what his comments/questions are.
Since he is a pioneer in this field and is doing nuclear transfer experiments all the time, including cross-species, I am sure he would love to get involved in this discussion.
notch1 said...
thank you,
West just a good businessman (i guess he is CEO), probably better can answer Robert Lanza, but anyway alot of labs doing NT and HSC differentiation from ES,
everybody who are in topic - welcome!
Sergei said...
Unnfortunately, unfortunately dont have full text but from abstract still unclear why donors oocytes were enucleated, what donor cumulus cells were used, etc. Very obscure abstract. Sure no risk of teratomas anyway because ESC couldn't from them.
Differentiation is even more unclear. From the abstract it looks that people took oocytes, same but diploid nucleus coculture ICM and injected in the poor guy with promisses that he will survive after all.
Vikram said...
Are you using adut stem cells for regrowing kidney or reparing shrunken or damaged kidney?
ghanshyam mohanlal joshi said...
i heard in the news that can cure diabetic is it possible my daughter is 11 yrs 297469
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.
notch1 said...
thank you for open dialogue and discussion.
I have been rised question in my previous post when news was released.
Why authors don't use more appropriate protocol for HSC generation from ntES cells? If HSC is a point and it's realy increased donor chimerism.
Because no stromal cells (just total MNC), no cytokines gave only 7 percent CD34+ cells in finish.
And how authors can exclude possibility of graft contamination by BM cells (HSC can come from BM and mature immune cells) in coculture condition described in paper?
thanks